Liquidia (NASDAQ:LQDA) Posts Earnings Results, Beats Expectations By $0.07 EPS

Liquidia (NASDAQ:LQDA) announced its quarterly earnings data on Thursday. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07, FiscalAI reports. Liquidia had a negative net margin of 43.53% and a negative return on equity of 237.79%. The business had revenue of $92.02 million for the quarter, compared to analyst estimates of $87.49 million. The business’s quarterly revenue was up 3072.4% on a year-over-year basis.

Here are the key takeaways from Liquidia’s conference call:

• Liquidia reported strong commercial profitability with full‑year 2025 net product sales of $148.3M (Q4 $90.1M), non‑GAAP adjusted EBITDA of $27.3M, net income of $14.6M, and approximately $190.7M cash after generating $33M positive cash flow in Q4.
• The launch momentum remains robust: >3,600 unique referrals and >2,900 patient starts through Feb‑28, and estimated inhaled‑treprostinil revenue share rising from ~10% in Q3 to ~17% in Q4, with 75% of starts prostacyclin‑naïve.
• Management plans multiple near‑term clinical programs to expand use and labeling (switch studies from oral/inhaled prostacyclins, adjunctive combinations, new indications like systemic sclerosis‑associated Raynaud’s and PH‑COPD) and will advance the next‑gen L‑606 pivotal study — all expected to be funded by operating cash flow and target building a >$1B franchise by 2027.
• Company downplays competitive threats from a recently announced soft‑mist inhaler (SMI) and new oral agents, arguing limited clinical/tolerability advantage for rivals, but competitor data are still evolving so the market impact remains uncertain.
• No new update on the ongoing IP/legal matter since the post‑trial briefing; management says it is confident but a judicial opinion timing is uncertain, representing potential downside risk if unfavorable.

Liquidia Stock Performance

NASDAQ LQDA opened at $36.03 on Friday. The firm has a market capitalization of $3.13 billion, a P/E ratio of -43.41, a price-to-earnings-growth ratio of 0.62 and a beta of 0.52. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The firm’s fifty day moving average price is $37.10 and its two-hundred day moving average price is $30.92. Liquidia has a 1 year low of $11.26 and a 1 year high of $46.67.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Analyst Upgrades and Downgrades

LQDA has been the topic of several recent research reports. BTIG Research lifted their price target on shares of Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research note on Thursday. Jefferies Financial Group raised their price objective on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, January 13th. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 27th. Finally, Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $42.00.

Insider Buying and Selling

In related news, insider Rajeev Saggar sold 21,142 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $791,345.06. Following the completion of the sale, the insider directly owned 176,883 shares in the company, valued at approximately $6,620,730.69. This trade represents a 10.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel Russell Schundler sold 27,289 shares of Liquidia stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $1,021,427.27. Following the transaction, the general counsel owned 579,394 shares of the company’s stock, valued at $21,686,717.42. The trade was a 4.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 212,534 shares of company stock worth $7,964,719. Corporate insiders own 26.50% of the company’s stock.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently bought and sold shares of the business. Federated Hermes Inc. bought a new position in shares of Liquidia during the 3rd quarter worth approximately $7,290,000. Caprock Group LLC bought a new stake in Liquidia in the 3rd quarter valued at $37,114,000. Campbell & CO Investment Adviser LLC acquired a new stake in Liquidia during the 3rd quarter valued at $2,026,000. Tyro Capital Management LLC acquired a new stake in Liquidia during the 2nd quarter valued at $15,473,000. Finally, XTX Topco Ltd bought a new position in Liquidia during the second quarter worth $1,485,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).